What Technion Research & Development Foundation does

Technion Research & Development Foundation (TRDF, מוסד הטכניון למחקר ופיתוח בע"מ) is the official technology transfer office and research administration arm of the Technion-Israel Institute of Technology, headquartered on the Technion campus in Haifa, Israel. Founded in 1952, it operates multiple functional units: the Research Authority (research promotion, EU and national calls for proposals, research ethics), T3 (technology translation and commercialization), TechConnect (industry liaison and partnership development), the Continuing Education School, and the Israel Institute for Manufacturing Materials Technologies (IMT). Its mandate is to bridge academic research at Technion with commercial applications, manage intellectual property, and channel industry collaborations. The foundation is governed by a small core staff (1–10 employees in the disclosed firmographics) and is organizationally housed within the public university structure.

TRDF's commercial technology portfolio centers on licensable university-developed IP. The most notable asset is the Nol8 "data-in-motion" engine, which processes data at microsecond-grade latency and delivers up to 400x latency improvement over conventional approaches, initially targeting the US$455 billion gaming market with broader stated applications for AI and autonomous systems. The second flagship is a patent-protected extracellular vesicle (exosome) production technology with batch-consistency results confirmed through proteomic analysis, advancing toward a potential investigational new drug (IND) application. Beyond these headline technologies, TRDF continuously licenses Technion-developed IP and provides entrepreneurship support to spin-off companies.

The foundation's revenue mechanics are licensing- and royalty-based, with monetisation executed through exclusive licensing agreements (e.g., the Nol8 license to FortifAI structured with 155 million shares plus 150 million performance rights), regional sublicenses (e.g., Exo-Top Inc. for North American exosome commercialization), collaborative research arrangements, continuing education programs, and equity stakes in spin-off companies. Customer-facing segments are primarily industry partners and corporations licensing Technion technologies and Technion's internal researchers/faculty whose work requires IP protection and commercialization pathways. Revenue figures are not publicly disclosed, and pricing is negotiated deal-by-deal rather than through a published price list.

Name

Technion Research & Development Foundation

Legal name

מוסד הטכניון למחקר ופיתוח בע"מ

Website

https://trdf.co.il

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

1–10 employees

Short description

Technion Research & Development Foundation (TRDF) is the technology transfer and research commercialization arm of the Technion-Israel Institute of Technology in Haifa, Israel. It licenses university-developed IP — including the Nol8 data-in-motion engine and extracellular vesicle production technology — to industry partners, sublicensees, and spin-off companies.

Ownership category

akta.pro rank

Product category

Technology Transfer Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Professional, Scientific, and Technical Services (54), Computer Systems Design and Related Services (54151)

SIC

Patent Owners & Lessors (6794), Services-Commercial Physical & Biological Research (8731), Services-Engineering Services (8711)

akta.pro primary industry

IP Licensing, Transactions & Technology Transfer (BPAHAMAF)

akta.pro secondary industries

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH), Process Development & Tech Transfer Services (CDMO) (HLAGABAL), Systems Engineering & Technical Program Management (BPAHAIAI)

Keywords

• Technology transfer
• Research commercialization
• IP licensing
• Industry partnerships
• Academic research

Headquarters

HQ city

Haifa

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Technology Licensing and Commercialization: TRDF serves as the technology transfer and commercialization arm of Technion, licensing university-developed technologies to industry partners, startups, and commercial entities. Revenue generated through licensing fees, royalties, equity stakes in spin-offs, and sublicense agreements.
2. IP Licensing (Nol8 Technology): Exclusive licensing of Technion-developed technologies such as the Nol8 data-in-motion platform to external companies like FortifAI, structured with share compensation and performance-based payments.

Distribution channels3 records

Marketing channels3 records

Core offering

TRDF provides the administrative and financial framework for research activities at Technion-Israel Institute of Technology. It manages technology transfer, IP licensing, industry collaborations, and commercialization of university-developed technologies through multiple units including the Research Authority, T3 Entrepreneurship and Innovation Center, TechConnect, Continuing Education School, and IMT.

Product overview

Technion Research & Development Foundation (TRDF) operates as a multi-unit research and technology transfer organization, not a single software product. The foundation comprises several distinct operational units: the Research Authority manages research promotion and calls for proposals; T3 handles technology translation and entrepreneurship; TechConnect manages industry relations and training; the Continuing Education School provides professional programs; and the Israeli Institute for Manufacturing Materials Technologies (IMT) focuses on materials technology. Additionally, TRDF has developed/licensed technologies including the Nol8 data-in-motion processing technology with microsecond-grade latency capabilities, and holds patents for extracellular vesicle production technology.

Differentiator

Problem solved

Functional benefit

Brands

• T3 (Technion Technology Translation): Business unit focused on technology transfer and commercialization of research innovations from Technion.
• ביה"ס ללימודי המשך (School for Continuing Studies)
• IMT - Israel Institute of Material Technologies
• קשרי תעשייה (TechConnect)

Products and services

• Research Authority
• T3 Entrepreneurship and Innovation Center
• TechConnect
• Continuing Education School
• IMT
• Nol8 Data-in-Motion Technology License
• Extracellular Vesicle Production Technology License

Quantifiable outcome

• Up to 400x latency improvement with Nol8 technology
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• NurExone Biologic Inc.coreTechnology or Integration · 1 June 2026TRDF serves as the technology transfer office supporting Technion researchers whose technologies are commercialized by companies like NurExone. The partnership involves sublicense agreements with NurExone's U.S. subsidiary Exo-Top Inc. for extracellular vesicle production technology, with batch-consistency results from proteomic analysis conducted at Technion advancing regulatory and manufacturing roadmap toward potential IND application.
• BioXtek Inc.minorStrategic or Co-development Partner · 1 June 2026Non-binding letter of intent signed with Florida-based BioXtek Inc. to explore strategic partnership for exosome manufacturing and commercialization in North America. The LOI represents preliminary discussions for potential regional commercialization collaboration.
• FortifAI (via FastAI acquisition)coreTechnology or Integration · 15 December 2025TRDF granted exclusive license to Nol8 'data-in-motion' technology developed by Technion-Israel Institute of Technology. FortifAI acquired Perth-based FastAI to secure this exclusive license, with TRDF and FastAI shareholders receiving 155 million shares plus 150 million performance rights tied to ongoing development and commercialization. The Nol8 engine processes data with microsecond-grade latency and up to 400x latency improvement, targeting the US$455 billion gaming market with broader applications for AI and autonomous applications.
• Exo-Top Inc.coreTechnology or IntegrationU.S. subsidiary of NurExone Biologic Inc. operating as the sublicensee for extracellular vesicle production technology developed with Technion research support. Represents the North American commercialization vehicle for Technion-developed exosome technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Yeda Research and Development Company: Technology transfer office of the Weizmann Institute of Science, operating the same model as TRDF: licensing Weizmann-developed technologies to industry, taking equity in spin-offs, and generating royalty revenue. Direct Israeli counterpart and most comparable peer.
• Ramot: Tel Aviv University's technology transfer company, handling IP protection, licensing, and spin-off creation for TAU researchers. Runs an identical business model to TRDF and is a direct competitor for industry partnerships and startup formation in Israel.
• BGN Technologies: Ben-Gurion University of the Negev's technology transfer company, commercializing BGU research through licensing and spin-offs. Another Israeli university TTO operating the same model as TRDF.
• BIRAD (Hebrew University Technology Transfer): Hebrew University's technology transfer arm, managing IP licensing and commercialization of HU research. Same university TTO model as TRDF, with strength in biotech/pharma licensing.
• Cambridge Enterprise: University of Cambridge's technology transfer office, offering a directly comparable model of IP licensing, equity holdings in spin-outs, and research commercialization services. Represents a global benchmark TTO.
• Oxford University Innovation: University of Oxford's technology transfer company, providing IP licensing, spin-out support, and research consulting services. Equivalent in scope and function to TRDF at a larger institution.

Broad incumbents

• MIT Technology Licensing Office: MIT's TLO is a much larger, globally dominant university technology transfer operation. While operating the same licensing model as TRDF, MIT TLO's scale, deal volume, and spin-off ecosystem make it a broader incumbent reference point.
• Stanford Office of Technology Licensing (OTL): Stanford's TLO manages IP licensing from Stanford research, with a track record of generating significant royalty flows (e.g., biotech, software). Comparable model to TRDF but at a substantially larger scale and broader industry footprint.

Regional players

• Integra Holdings: Israeli biomedical holdings company that invests in and commercializes university and hospital-invented life-sciences technologies. Overlaps with TRDF's therapeutic IP commercialization (e.g., exosome space) and is a regional competitor for biotech licensing deals.
• NurExone Biologic Inc. Canadian biotech commercializing exosome-based therapeutics and a current TRDF sublicensee via its U.S. subsidiary Exo-Top Inc. While a partner rather than a competitor, it operates in the same therapeutic exosome space that TRDF's IP enables, making it a related commercialization participant.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@%D7%9E%D7%95%D7%A1%D7%93%D7%94%D7%98%D7%9B%D7%A0%D7%99%D7%95%D7%9F-%D7%A93%D7%99
• Facebookfacebook.com/Technion.RnD
• LinkedInlinkedin.com/company/8777856/admin

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Technion Research & Development Foundation